Leukapheresis Market Outlook:
Leukapheresis Market size was valued at USD 3.22 billion in 2025 and is expected to reach USD 7.76 billion by 2035, registering around 9.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of leukapheresis is evaluated at USD 3.49 billion.
The demand for leukapheresis is driven by an increasing incidence of leukemia, as leukapheresis is a critical medical procedure to trealeukemia. As per a report, in 2023, there will be 1,958,310 new cancer cases diagnosed in the US; of these, leukemia, lymphoma, and myeloma cases are predicted to make up 9.4%. Leukapheresis is a procedure to remove white blood cells that may be used for other medical purposes, such as stem cell transplantation and immunotherapy. The need for leukapheresis to support these treatments is increasing as the incidence of leukemia increases, and this has led to an increase in sales.
Leukapheresis can be performed to harvest stem cells from children for other cancer patients as well as to treat or eliminate excess WBCs in children with lymphoma. Leukapheresis is a market focus because of its potential and advantages in this application, particularly as children's leukapheresis treatment is now only available in a small number of hospitals in developed and developing nations. Therefore, this factor is propelling the growth of the leukapheresis market.
